Lipid Effects of Psychiatric Medications

Nonstatin Drugs (WB Borden, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Nonstatin Drugs


People with schizophrenia have higher rates of medical illness and mortality than the general population. Cardiovascular disease is a major contributor to premature death in patients with schizophrenia. There has been an increase literature discussing the high prevalence of dyslipidemia, which is one of risk factors for cardiovascular disease, induced by second generation antipsychotic agents. Depression is associated with increased risks of diabetes, hypertension, cardiovascular disease. However, those may not be secondary to the use of antidepressant agents. In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. Further investigations are needed to evaluate the effects of antidepressive agents on lipid profiles.


First generation antipsychotic agents Second generation antipsychotic agents Antidepressive agents Dyslipidemia Lipid profiles Monitoring 


Papers of particular interest that have been published recently are indicated as follows: • Of importance•• Of major importance

  1. 1.
    Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatr Suppl. 2004;47:S102–5.CrossRefGoogle Scholar
  2. 2.
    Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol. 2005;19:47–55.PubMedCrossRefGoogle Scholar
  3. 3.
    McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.Google Scholar
  4. 4.
    Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.PubMedCrossRefGoogle Scholar
  5. 5.
    Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66:848–56.Google Scholar
  6. 6.
    Viron MJ, Stern TA. The impact of serious mental illness on health and healthcare. Psychosomatics. 2010;51:458–65.PubMedGoogle Scholar
  7. 7.
    Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatr. 1991;36:239–45.Google Scholar
  8. 8.
    Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45:21–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002;71:239–57.PubMedCrossRefGoogle Scholar
  11. 11.
    Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatr. 2004;65:715–20.CrossRefGoogle Scholar
  12. 12.
    Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.Google Scholar
  13. 13.
    George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatr Res. 2001;101:277–88.CrossRefGoogle Scholar
  15. 15.
    Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–96.PubMedGoogle Scholar
  16. 16.
    Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatr. 1999;60:215–20.CrossRefGoogle Scholar
  17. 17.
    Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22:244–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatr. 2001;62 Suppl 27:27–34. discussion 40–21.Google Scholar
  19. 19.
    Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003;26:1597–605.PubMedCrossRefGoogle Scholar
  20. 20.
    Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697–701.PubMedCrossRefGoogle Scholar
  21. 21.
    Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatr. 1996;37:68–73.CrossRefGoogle Scholar
  22. 22.
    Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses—a comparison between different antipsychotic agents. Psychopharmacology (Berl). 2001;154:205–12.CrossRefGoogle Scholar
  23. 23.
    Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157:975–81.PubMedCrossRefGoogle Scholar
  24. 24.
    Pan A, Lucas M, Sun Q, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010;170:1884–91.PubMedCrossRefGoogle Scholar
  25. 25.
    Patten SB, Williams JV, Lavorato DH, et al. Major depression as a risk factor for high blood pressure: epidemiologic evidence from a national longitudinal study. Psychosom Med. 2009;71:273–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.PubMedCrossRefGoogle Scholar
  27. 27.
    • Pan A, Sun Q, Okereke OI, et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA. 2011;306:1241–9. They described the relationship between depressive disorder and cardiovascular disease.PubMedCrossRefGoogle Scholar
  28. 28.
    Salaycik KJ, Kelly-Hayes M, Beiser A, et al. Depressive symptoms and risk of stroke: the Framingham Study. Stroke. 2007;38:16–21.PubMedCrossRefGoogle Scholar
  29. 29.
    Shimbo D, Chaplin W, Crossman D, et al. Role of depression and inflammation in incident coronary heart disease events. Am J Cardiol. 2005;96:1016–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Strine TW, Mokdad AH, Dube SR, et al. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. Gen Hosp Psychiatr. 2008;30:127–37.CrossRefGoogle Scholar
  31. 31.
    • Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220–9. They described the relationship between depressive disorder and cardiovascular disease.PubMedCrossRefGoogle Scholar
  32. 32.
    Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91:465–71.PubMedCrossRefGoogle Scholar
  33. 33.
    •• Liao CH, Chang CS, Wei WC, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011;126:110–6. It investigated the risks of developing diabetes mellitus, hypertension, and hyperlipidemia in treating schizophrenia with first and second generation antipsychotics. The effect of antipsychotic agents on lipid metabolism is a serious concern in psychiatric medication and their study is important.Google Scholar
  34. 34.
    Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatr. 2002;63:425–33.CrossRefGoogle Scholar
  35. 35.
    Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009;111:9–16.PubMedCrossRefGoogle Scholar
  36. 36.
    Duncan EJ, Woolson SL, Hamer RM, et al. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol. 2009;24:204–13.PubMedCrossRefGoogle Scholar
  37. 37.
    Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–31.PubMedCrossRefGoogle Scholar
  38. 38.
    Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996;53:2079–81.PubMedGoogle Scholar
  39. 39.
    Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168:947–56.PubMedCrossRefGoogle Scholar
  40. 40.
    Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596–601.Google Scholar
  41. 41.
    Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatr. 2004;49:753–60.Google Scholar
  42. 42.
    McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.PubMedCrossRefGoogle Scholar
  43. 43.
    Mackin P, Bishop D, Watkinson H, et al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry. 2007;191:23–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Watanabe J, Suzuki Y, Sugai T, et al. The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents. Gen Hosp Psychiatr. 2012;34:525–8.CrossRefGoogle Scholar
  45. 45.
    Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519–26.PubMedCrossRefGoogle Scholar
  46. 46.
    de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 2007;92:95–102.PubMedCrossRefGoogle Scholar
  47. 47.
    Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008;28:132–7.PubMedCrossRefGoogle Scholar
  48. 48.
    McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802–9.PubMedGoogle Scholar
  49. 49.
    Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193–205.PubMedCrossRefGoogle Scholar
  50. 50.
    Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006;116:1813–22.PubMedCrossRefGoogle Scholar
  51. 51.
    Domon SE, Webber JC. Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacol. 2001;11:285–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatr. 2002;41:495–6.CrossRefGoogle Scholar
  53. 53.
    Nguyen M, Murphy T. Olanzapine and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatr. 2001;40:133.CrossRefGoogle Scholar
  54. 54.
    Wetterling T. Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)? Psychiatr Prax. 2002;29:438–40.PubMedCrossRefGoogle Scholar
  55. 55.
    Jerrell JM, Tripathi A, Rizvi AA et al. The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis. Prim Care Companion CNS Disord 2012, 14.Google Scholar
  56. 56.
    • Pyykkonen AJ, Raikkonen K, Tuomi T, et al. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study. Ann Med. 2012;44:279–88. The relationship between depressive disorder and cardiovascular disease may not be driven by the use of antidepressive agents.Google Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Junzo Watanabe
    • 1
  • Yutaro Suzuki
    • 1
  • Toshiyuki Someya
    • 1
  1. 1.Department of PsychiatryNiigata University Graduate School of Medical and Dental SciencesNiigataJapan

Personalised recommendations